{"name":"Certmedica International GmbH","slug":"certmedica-international-gmbh","ticker":"","exchange":"","domain":"certmedicainternationalgmbh.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Polyglucosamine L112","genericName":"Polyglucosamine L112","slug":"polyglucosamine-l112","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Polyglucosamine L112","genericName":"Polyglucosamine L112","slug":"polyglucosamine-l112","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQelpESVIyWjFjNVhEQ1JoVmtNaWc3QkNCSWtZRUsza0xqT2RaWjBQcjB6bE5Qd2QxTXJ2Y1JhTHZCYmIxRDJvNlBlU1JBRUtBYk5mM2cxbXYzSk83blB0Z211Yi1ncEVWNlRsd3BzT3VlYl9sM0ZNRFpPZTN5a3BjT0NaVHpnX0U0MFdOeHBocFpVSGd0RTlqNWZLUjIxSjFWOV93WlljU2lPR3BmX1lEaV8zNUhxNUFtaVpDTGVEWk8?oc=5","date":"2026-01-29","type":"pipeline","source":"Mynewsdesk","summary":"Intermittent fasting reimagined with formoline Intervall 5:2 - Mynewsdesk","headline":"Intermittent fasting reimagined with formoline Intervall 5:2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOTXpvQy1keHRLQlM4NTc2aFBERjRTbTkxRXRHOVBPZUhWbTZuNXl3ekkyN2xzb3oyaFJlcFJmVk56WGl2dlRTYllnSU5ndU9FbEVIZ0k2MXF2dzl6QWN5TEtoWmE2aHdKMzdoMHU4UGJtQ2dNWmNqV2pHckljb1RsUC1wcWYyRkJ1OVlLZ1FPR0lWbkZPVE12emxncGJUY09tYmR5TkVucWdlS1psRlpaSnhNNVJ3MGttSlZEdkY2cy12OVg4SkJ5TVlQT1dpVUlzaUZzX0hWN1B5Z2p3NUpfNjdDWGdUTkdkVW92UGdRQk5lMllsWEw4c0R3?oc=5","date":"2025-03-27","type":"regulatory","source":"Mynewsdesk","summary":"Certmedica enters the Mexican market after COFEPRIS approved formoline L112 as class III medical device - Mynewsdesk","headline":"Certmedica enters the Mexican market after COFEPRIS approved formoline L112 as class III medical device","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNX2NxdlhLalI2MFhOOHJBTS1manlkQzFuUV85QTZrd2NRLWVSWXhxSnhONExCcFVZU2t3QzBPUGMwNXpjS1ZRQW5ESzVXczV4d2FxYm1RWDZOYWZleWZpc1gyTGx5RWNqeDZwY25LbXlZaWdJN2IxeE9tUlVsX1VMdlkwWGRuS2xiQkNfN3JYbVlxM3RqR0VVUWRsV1E4aldpZnM5dXBXaEo5NmZ6NFlJUlhVY1l6bVBCbkhINUJvSXI3Zw?oc=5","date":"2025-02-28","type":"pipeline","source":"Mynewsdesk","summary":"Certmedica supports digital weight loss with My-formoline app - Mynewsdesk","headline":"Certmedica supports digital weight loss with My-formoline app","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}